<DOC>
	<DOCNO>NCT01886209</DOCNO>
	<brief_summary>This study design evaluate effect VX-509 pharmacokinetics ( PK ) corticosteroid ( prednisone methylprednisolone ) effect corticosteroid PK VX-509 metabolite . The study also evaluate safety tolerability VX-509 coadministered corticosteroid .</brief_summary>
	<brief_title>Phase 1 PK Interaction Study Between VX-509 Prednisone Methylprednisolone Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Male subject 18 55 year age , inclusive Body mass index ( BMI ) 18.0 31.0 kg/m2 , inclusive , total body weight &gt; 50 kg History illness , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug ( ) subject . This may include , limited , history cardiovascular central nervous system disease , diabetes , history presence clinically significant pathology , history mental disease Treatment investigational drug within 30 day 5 halflives precede first dose study drug Subject female partner pregnant , nursing , plan become pregnant study within 90 day last dose study drug Positive test result follow infectious disease test Screening Visit : TSPOT tuberculosis ( TB ) test , hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus 1 2 antibody</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>